You are here: Industry Insights > Adaptimmune

News List

PRIME status for Adaptimmune's synovial sarcoma drug pharmatimes
July 28, 2020
The European Medicines Agency (EMA) has awarded Adaptimmune's ADP-A2M4 PRIME status for the treatment of synovial sarcoma.
Astellas, Adaptimmune to Co-Develop, Commercialize CAR-T and TCR T-Cell Therapies americanpharmaceuticalreview
January 19, 2020
Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics have entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.
Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer pharmaceutical-business-review
January 17, 2020
Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.
Rawcliffe to Succeed Noble as Adaptimmune CEO contractpharma
July 17, 2019
Noble will transition to become a Non-Executive Director.
Adaptimmune, Alpine Immune Sciences Enter Next-Gen SPEAR T-Cell Pact contractpharma
May 16, 2019
Adaptimmune to license Alpine’s Immunomodulatory Protein technology for use with SPEAR T-cells to enhance anti-tumor responses.
Adaptimmune Sees Positive Early Results in Cancer Treatment biospace
March 19, 2018
Adaptimmune Ltd. shares rose late Thursday
Adaptimmune's CMO Moves Forward With SPEAR T Cell Therapies biospace
January 11, 2018
The new year, based on the British Adaptimmune Ltd., has successfully produced the first SPEAR-T cells to be used in multiple tumor research